← Animal Welfare Hub
Cardiac Disease in Cats: Welfare Management
Feline Heart Disease and Welfare
Cardiac disease is a significant cause of morbidity and mortality in cats. Unlike dogs, cats most commonly suffer from hypertrophic cardiomyopathy (HCM) — thickening of the heart muscle — rather than valvular disease. Management of feline cardiac disease requires understanding the species-specific presentations and treatment challenges.
Hypertrophic Cardiomyopathy (HCM)
- Prevalence: Most common cardiac disease in cats; affects approximately 15% of cats, with much higher prevalence in certain breeds (Maine Coon, Ragdoll, British Shorthair).
- Pathophysiology: Thickening of left ventricular wall reduces cardiac chamber volume and compliance; impairs filling and cardiac output.
- Progression: Many cats remain asymptomatic for years; others develop congestive heart failure (CHF) or aortic thromboembolism (ATE).
- Genetic testing: MYBPC3 mutation testing available for Maine Coon and Ragdoll cats — breeding programmes should exclude affected cats.
Welfare Impacts
- Congestive heart failure: Fluid accumulation in chest (pleural effusion) or lungs causes respiratory distress — acute, severe welfare emergency.
- Aortic thromboembolism (ATE): Blood clot lodging at aortic bifurcation causes sudden, extremely painful hindlimb paralysis — one of the most acute welfare emergencies in companion animal practice.
- Syncope: Fainting episodes are frightening for both cat and owner.
- Reduced exercise tolerance: Limits normal behaviour in affected cats.
Management
- Diuretics: Furosemide for CHF management — reduces fluid accumulation and respiratory distress.
- Atenolol: Used in some cases to manage heart rate; evidence base evolving.
- Clopidogrel (Plavix): Antiplatelet therapy significantly reduces ATE recurrence risk in cats with left atrial enlargement (FATCAT study evidence).
- ACE inhibitors: Controversial evidence in HCM — not universally recommended.
- Monitoring: Echocardiography every 6-12 months; NT-proBNP blood test as a screening and monitoring tool.
- ATE management: Extremely challenging welfare decision — pain management, physiotherapy, and honest prognosis discussion with owners.
Key Takeaways
Feline cardiac disease, particularly HCM, requires proactive monitoring and breed-appropriate genetic testing. Medical management can extend comfortable life in CHF; antiplatelet therapy reduces ATE recurrence. ATE itself requires an honest welfare and quality of life discussion that may include euthanasia as a compassionate option.